Symbolic representation of healthy to dysplastic transformation in a tree, symbolizing oral health after stem cell transplant.

Oral Dysplasia After Stem Cell Transplants: What You Need to Know

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"A closer look at HPV-related oral dysplasia in multiple myeloma patients following stem cell transplantation."


Stem cell transplants offer hope for many battling hematological malignancies, yet they can also bring long-term complications. One such concern is the development of dysplastic changes in oral epithelial lesions. These changes, while not always cancerous, require vigilant monitoring and understanding.

A recent case highlights the potential link between stem cell transplantation, chronic graft-versus-host disease (cGVHD), and HPV-related oral dysplasia. The case involves a 54-year-old male with multiple myeloma who, after undergoing both autologous and allogenic HSCT, developed cGVHD and subsequent oral dysplasia.

This article explores the details of this case, shedding light on the risk factors, the role of HPV, and the importance of clinical follow-ups for individuals who have undergone stem cell transplantation.

AI Search Multiple angles on this topic

Why STEM Terminology Does Not Establish Clinical Statistics

The supplied sources define STEM as an umbrella term for science, technology, engineering, and mathematics. They do not provide statistics about oral dysplasia after stem cell transplantation, transplant recipients, cancer risk, or patient outcomes. Consequently, no clinically meaningful prevalence or impact estimate can be established from these sources.

Limits of the Available Evidence

The supplied source describes STEM education as a way to develop future-ready skills through science, technology, engineering, and mathematics lessons. It does not discuss oral examinations, biopsy, surveillance, treatment, or other clinical methods for oral dysplasia after transplantation. Any description of accepted medical approaches or their limitations would therefore require different sources.

Historical Evidence Gap

The available material does not document the history of oral dysplasia after stem cell transplantation. It also does not identify relevant medical milestones, foundational discoveries, or historical changes in transplant-related oral care. A reliable historical account would need dedicated clinical and biomedical sources.

Unpacking the Link: Stem Cell Transplants and Oral Dysplasia

Symbolic representation of healthy to dysplastic transformation in a tree, symbolizing oral health after stem cell transplant.

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow. Allogeneic hematopoietic stem cell transplant (HSCT) is a treatment option that gives patients a chance at long-term survival. However, oral complications are common after HSCT. Chronic graft-versus-host disease (cGVHD) is often seen with symptoms like lichenoid inflammation, hyperkeratotic reticulations, and ulcerations.

The case study highlights a 54-year-old male who, after undergoing HSCT, developed cGVHD affecting his mouth, skin, and eyes. He presented with diffuse white lesions on his buccal mucosa, tongue, and palate. A biopsy revealed moderate to severe epithelial dysplasia with hyperkeratosis, and tested positive for p16INK4A, indicating the presence of human papillomavirus (HPV).

  • Radiation and Chemotherapy Regimens: The intensity of these treatments can weaken the immune system.
  • Chronic Graft-versus-Host Disease (cGVHD): This condition, where the transplanted cells attack the host's tissues, can cause inflammation and damage in the oral cavity.
  • Inflammation: Chronic inflammation can create an environment conducive to dysplasia.
  • Prolonged Immunosuppression: Transplant recipients often require immunosuppressant drugs to prevent rejection, further weakening their defenses against infections like HPV.
AI Search Multiple angles on this topic

Research Evidence Not Supplied

No source material was provided for recent research or reviews of oral dysplasia after stem cell transplantation. The available excerpts concern STEM education rather than oral medicine, transplantation, pathology, or oncology. Current findings therefore cannot be summarized responsibly from the supplied material.

No Clinical Counterevidence Available

The supplied material does not examine disagreements, failed interventions, diagnostic limitations, or counterarguments concerning oral dysplasia after stem cell transplantation. It provides no clinical cases or outcome data for evaluating competing claims. Any discussion of failures would require sources specific to this medical topic.

No Medical Comparisons Supported

The available sources do not compare screening strategies, transplant groups, treatments, or oral dysplasia outcomes. Their comparisons are limited to STEM and STEAM as educational concepts, with STEAM adding the arts to STEM. Those educational distinctions cannot support a medical comparison.

The presence of HPV is a significant factor in this case. Certain types of HPV are known to cause dysplastic changes, which are abnormal cell growths that can potentially lead to cancer. Immunosuppression can increase the risk of HPV infection or reactivation, making transplant recipients more vulnerable.

Staying Proactive: What This Means for You

If you've undergone a stem cell transplant, particularly for multiple myeloma, it's essential to be proactive about your oral health. Regular dental check-ups are crucial for early detection of any abnormalities. Discuss any changes in your mouth with your dentist or oncologist. Early detection and intervention are key to managing oral dysplasia and preventing potential complications.

AI Search Multiple angles on this topic

Evidence-Based Synthesis Requires Clinical Sources

A responsible synthesis of oral dysplasia after stem cell transplantation cannot be developed from the supplied sources. The material discusses STEM education and does not include expert commentary from oral medicine, transplantation, pathology, or oncology. Clinical interpretation should therefore be deferred until relevant evidence is supplied.

Future Directions Remain Unspecified

The supplied sources do not address future research, emerging diagnostics, new treatments, or technological frontiers in oral dysplasia after stem cell transplantation. They discuss innovation and critical thinking in STEM education, but do not connect those ideas to transplant medicine. Specific forecasts would be unsupported without dedicated medical research.

Systemic Context Not Documented

No supplied source describes healthcare access, survivorship systems, clinical workforce issues, or other systemic challenges affecting oral dysplasia after transplantation. The available material instead presents STEM as a group of technical disciplines and STEAM as an expanded educational approach. These definitions do not establish the broader healthcare context for this condition.

Patient Impact Not Covered

The supplied sources do not describe patients' symptoms, experiences, quality of life, treatment burdens, or outcomes after stem cell transplantation. They focus on educational skills such as critical thinking, problem-solving, and real-world learning. Patient-centered discussion of oral dysplasia therefore requires medical and lived-experience sources not included here.

What the case report examined

PopulationA 54-year-old male with multiple myeloma treated by autologous and allogenic HSCT[1]
Main outcomeModerate to severe epithelial dysplasia with hyperkeratosis, positive for p16INK4A[1]
Times cited4[1]

How this case fits with related oral-health evidence

A separate trial tested chamomile mouthwash for oral mucositis, a different outcome from dysplasia. Its reported improvement in mucositis does not establish an effect on dysplasia or HPV.[2]

A review reported pooled HPV DNA prevalence in oral epithelial dysplasia, while a diagnostic paper reported HPV test results in specimens; these measure HPV detection across different evidence sets, not risk after transplantation.[3] [4]

A systematic review and meta-analysis identified cGVHD among factors associated with secondary oral squamous cell carcinoma after allogeneic HSCT. That outcome is cancer, not the dysplasia described in this case.[5]

Questions the case leaves open

  • Would similar oral lesions and dysplasia findings appear in a broader group of people after allogeneic HSCT, or was this case unusual?[1]
  • How often does HPV accompany oral dysplasia in transplant recipients, and how does that compare with other groups?[1] [3]
  • What is the malignant-transformation risk for dysplasia in the setting of cGVHD?[5] [6]

Terms used in the evidence

p16INK4A
A surrogate marker used in the case report.[1]

Sources

  1. HPV‐related oral dysplasia in a multiple myeloma patient after stem cell transplantation (Wiley, 2018)
  2. Use of Chamomilla recutita in the Prevention and Treatment of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation (Cancer Nursing, 2014)
  3. Oral HPV-associated dysplasia: is koilocytic dysplasia a separate entity? (pmc.ncbi.nlm.nih.gov)
  4. Human Papillomavirus-Associated Oral Epithelial Dysplasia: A Practical Approach to Make the Diagnosis (pmc.ncbi.nlm.nih.gov)
  5. A Systematic Review and Meta-Analysis of Risk Factors for Secondary Oral Squamous Cell Carcinoma After Allogeneic Hematopoietic Stem Cell Transplantation. (pubmed.ncbi.nlm.nih.gov)
  6. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1111/scd.12344, Alternate LINK

Title: Hpv-Related Oral Dysplasia In A Multiple Myeloma Patient After Stem Cell Transplantation

Subject: General Dentistry

Journal: Special Care in Dentistry

Publisher: Wiley

Authors: Wafaa Saleh, Seunghee Cha, Bhattacharyya Indraneel, Jan Moreb, Joseph Katz

Published: 2018-11-15

Everything You Need To Know

1

What is the connection between stem cell transplants and oral dysplasia, especially for multiple myeloma patients?

Stem cell transplants, particularly allogeneic hematopoietic stem cell transplants (HSCT), used as a treatment for multiple myeloma, can lead to oral complications such as oral dysplasia. Chronic graft-versus-host disease (cGVHD), a common sequel to HSCT, causes inflammation and damage in the oral cavity, creating an environment where dysplastic changes in oral epithelial lesions can develop. These changes, while not always cancerous, necessitate careful monitoring. The presence of human papillomavirus (HPV) can exacerbate this risk due to immunosuppression following the transplant.

2

How does HPV play a role in oral dysplasia after a stem cell transplant?

Human papillomavirus (HPV) is a significant factor in oral dysplasia following a stem cell transplant. Certain types of HPV are known to cause dysplastic changes, which are abnormal cell growths that can potentially lead to cancer. Immunosuppression, a consequence of transplant and necessary medications, increases the risk of HPV infection or reactivation, making transplant recipients more vulnerable to HPV-related oral dysplasia. The case study highlights how the detection of p16INK4A, a marker for HPV, is important in monitoring these patients.

3

What are the main risk factors that contribute to oral dysplasia in stem cell transplant recipients?

Several risk factors contribute to oral dysplasia in stem cell transplant recipients. These include the intensity of radiation and chemotherapy regimens, which weaken the immune system; chronic graft-versus-host disease (cGVHD), causing inflammation in the oral cavity; prolonged immunosuppression required to prevent transplant rejection; and the presence of human papillomavirus (HPV). These factors create an environment conducive to dysplasia, especially in individuals who have undergone allogeneic hematopoietic stem cell transplant (HSCT) for multiple myeloma.

4

What does chronic graft-versus-host disease (cGVHD) do in the context of stem cell transplants and oral health?

Chronic graft-versus-host disease (cGVHD) is a condition where transplanted cells attack the host's tissues, leading to inflammation and damage in various parts of the body, including the oral cavity. In the mouth, cGVHD can manifest as lichenoid inflammation, hyperkeratotic reticulations, and ulcerations. This chronic inflammation creates an environment that increases the risk of developing oral dysplasia, especially in patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT).

5

What proactive steps can individuals who have undergone a stem cell transplant take to monitor and prevent oral dysplasia?

Individuals who have undergone a stem cell transplant, particularly for multiple myeloma, should prioritize proactive oral health measures. Regular dental check-ups are crucial for the early detection of any abnormalities. Any changes in the mouth should be promptly discussed with a dentist or oncologist. Early detection and intervention are key to managing oral dysplasia and preventing potential complications. Since prolonged immunosuppression increases the risk of human papillomavirus (HPV) related issues, regular screenings may be beneficial.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.